NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS in England, the drugs spending watchdog says. Donanemab was hailed as a turning point in the disease last year. But the National Institute ...
UK regulator approves second Alzheimer's drug in months but government won't pay for it
Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to t
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.
New Alzheimer’s drugs should be available on NHS, says patient’s wife
A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like him will be able to access treatments. New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease.
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.
Alzheimer’s wonder drug faces NHS block over cost
The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare the new treatment for the disease safe for use but the rationing body for the health service will immediately rule that it is too expensive for NHS patients.
UK's medicines regulator approves Lilly's drug for early Alzheimer's
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's disease, the company said on Wednesday. Britain is the third major market where donanemab,
Alzheimer's £60k wonderdrug blocked on NHS over cost despite major breakthrough
Donanemab has been hailed as 'game changer' but the price tag has barred it from being available to nearly one million Brits.
'Incredibly disappointing': Pioneering Alzheimer’s drug blocked for widespread NHS use in England
A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending watchdog said it “does not currently demonstrate value for the NHS”. The news comes as the UK’s medicines regulator said donanemab could be licensed for use in the UK.
Neuroscientists Reveal New Alzheimer's 'Brain Maintenance' Skill
Researchers have used advanced brain-imaging techniques to determine whether language skills physically alters the brain's ...
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...
'Alzheimer's drugs will come too late for us'
A couple from Hull have called on the government to fund new Alzheimer's drugs, even though they say it will come "too late" ...
England’s Drug-Cost Watchdog Rejects Eli Lilly’s Alzheimer’s Drug
England’s drug-cost regulator rejected Eli Lilly’s Alzheimer’s drug for use in the country’s public health system, marking ...
Alzheimer’s Caregiver Conference to focus on support for caretakers
LAREDO, Tex. (KGNS) - As treatments for Alzheimer’s improve, the needs of caregivers are often missed. To help, the Alzheimer’s Association is holding the “Alzheimer’s Caregiving Balancing Act” ...
AMNY on MSN3h
Hundreds walk in Central Park to raise awareness for Alzheimer’s disease
Hundreds of participants gathered in Central Park on Saturday, Oct. 19, for a two-mile walk to raise awareness about ...
BBC News - 12:00 Alzheimer's drug, Manchester bombing case, water review - BBC Sounds
The latest news from the BBC.
Alzheimer's study in Seattle makes new findings for future therapies
In the heart of Seattle, some of the world’s most brilliant minds study the brain at the Allen Institute, where researchers ...